Only one in vivo study investigated statins as combination therapy in a preclinical murine model of osteosarcoma and reported a synergistic interaction with another hypocholesterolemic agent targeting HMGCR (apomine), resulting in an enhanced anti-tumor effect [12]. The gene discussed is HMGCR; the disease is osteosarcoma.